Managed Access Programs for SEG101, Crizanlizumab
NCT03720626 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-04-14
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to SEG101, Crizanlizumab
Conditions
Interventions
- DRUG
-
crizanlizumab
Patients receive crizanlizumab
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 12 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
NCT04611880 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
NCT05098028 ·Status: COMPLETED ·Phase: PHASE2
-
Follow-up Data of Patients Treated With XIGRIS® in France
NCT00803231 ·Status: COMPLETED
-
A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
NCT02633397 ·Status: COMPLETED ·Phase: PHASE2
-
Gene Therapy for X-linked Severe Combined Immunodeficiency
NCT01410019 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Gene Therapy for Severe Crigler Najjar Syndrome
NCT03466463 ·Status: RECRUITING ·Phase: NA
-
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
NCT04093349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Dose-Finding Study of SC411 in Children With Sickle Cell Disease
NCT02973360 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
NCT07287202 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy
NCT04718779 ·Status: COMPLETED ·Phase: PHASE4
-
The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2
NCT01123863 ·Status: COMPLETED
-
A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease
NCT04721366 ·Status: COMPLETED
-
VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Participants With Late-Onset Pompe Disease
NCT02898753 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
NCT00060515 ·Status: TERMINATED ·Phase: PHASE1
-
Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)
NCT04120506 ·Status: COMPLETED ·Phase: PHASE4
-
Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease
NCT03702361 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
NCT00635427 ·Status: COMPLETED ·Phase: PHASE3
-
Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
NCT05099874 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
NCT06518005 ·Status: RECRUITING ·Phase: PHASE2
-
Dosing Study of Replagal in Patients With Fabry Disease
NCT00068107 ·Status: COMPLETED ·Phase: PHASE2
-
Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.
NCT05470270 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2b Study of Zagociguat in Patients With MELAS
NCT06402123 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
NCT03566017 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
NCT06308718 ·Status: TERMINATED